Minerva Neurosciences | NERV - Operating Profit


Minerva Neurosciences reported $-21.85M in Operating Profit for its fiscal quarter ending in December of 2024.





Operating Profit Change Date
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Adma Biologics USD 52.44M 2.15M Jun/2026
ALKERMES USD 36.59M 102.52M Sep/2026
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
AstraZeneca USD 4.66B 1.5B Sep/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Cipla INR 10.43B 1.55B Sep/2026
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD -8.84M 180K Jun/2026
CSL USD 2.64B 1.97B Dec/2025
Eli Lilly USD 12.46B 2.68B Jun/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Grifols EUR 320.55M 91.01M Dec/2025
Halozyme Therapeutics USD -60.68M 3.04M Sep/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
J&J USD 6.47B 1B Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Novartis USD 5.14B 392M Sep/2026
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 662M 5M Sep/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 4.72B 2.34B Sep/2026
Takeda JPY 205.32B 3.9B Sep/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024